Effects of Vitamin D Supplementation in Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Overview

Journal Int J Prev Med

Date 2019 Mar 2

PMID 30820303

Citations 14

Authors

Mahsa Jalili

Homayoon Vahedi

Hossein Poustchi

Azita Hekmatdoost

Affiliations

Soon will be listed here.

Abstract

Objective: There are some evidence that Vitamin D supplementation may be beneficial for patients with irritable bowel syndrome (IBS). The aim of this study was to evaluate the effects of Vitamin D supplementation on symptoms and quality of life (QOL) in patients with IBS.

Methods: In a randomized, double-blind, placebo-controlled clinical trial, 116 patients with IBS were supplemented weekly with either a pearl of 50,000 IU Vitamin D or an identical pearl of placebo containing medium chain triglyceride for 6 weeks.

Results: Mean age of patients was 42.24 ± 12.26, and 40.06 ± 13.37 in Vitamin D and placebo groups, respectively. Dietary intakes were similar between and within groups. Serum concentration of 25-hydroxy Vitamin D increased significantly from 21.10 ± 5.23 to 36.43 ± 12.34 in the Vitamin D group ( < 0.001), while it was not significantly different before and after the trial in placebo group. The IBS symptoms severity scores (SSSs), disease-specific QOL, and total score were evaluated at weeks 0 and 6. IBS-SSS, IBS-QOL, and the total score were improved significantly more in Vitamin D group in comparison to the placebo group ( < 0.05).

Conclusions: This study indicates that Vitamin D therapy can improve the severity of symptoms and QOL in patients with IBS; however, the long-term effects remained to be elucidated. Trial registration at IRCT: IRCT201402234010N11 IRB Number: 116/3976.

Citing Articles

Placebo response variability on health-related quality of life outcomes in irritable bowel syndrome: an arm-based network meta-analysis.

Wang Z, Chen Y, Li X, Lin L, Chen B, Chen M Qual Life Res. 2025; .

PMID: 39998756 DOI: 10.1007/s11136-025-03927-w.

Clinical Toxicology of Vitamin D in Pediatrics: A Review and Case Reports.

Levita J, Wilar G, Wahyuni I, Bawono L, Ramadaini T, Rohani R Toxics. 2023; 11(7).

PMID: 37505607 PMC: 10385357. DOI: 10.3390/toxics11070642.

Vitamin D improves irritable bowel syndrome symptoms: A meta-analysis.

Yan C, Hu C, Chen X, Jia X, Zhu Z, Ye D Heliyon. 2023; 9(6):e16437.

PMID: 37260904 PMC: 10227324. DOI: 10.1016/j.heliyon.2023.e16437.

Strategies for Producing Low FODMAPs Foodstuffs: Challenges and Perspectives.

Galgano F, Mele M, Tolve R, Condelli N, Di Cairano M, Ianiro G Foods. 2023; 12(4).

PMID: 36832931 PMC: 9956220. DOI: 10.3390/foods12040856.

The efficacy of vitamin D supplementation for irritable bowel syndrome: narrow scope and GRADE miss-interpretation.

Abuelazm M, Abdelazeem B Nutr J. 2023; 22(1):8.

PMID: 36658580 PMC: 9854156. DOI: 10.1186/s12937-022-00833-6.

References

Drossman D, Dumitrascu D . Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis. 2006; 15(3):237-41. View

Kong J, Zhang Z, Musch M, Ning G, Sun J, Hart J . Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. 2007; 294(1):G208-16. DOI: 10.1152/ajpgi.00398.2007. View

Cantorna M . Why do T cells express the vitamin D receptor?. Ann N Y Acad Sci. 2010; 1217:77-82. PMC: 3129658. DOI: 10.1111/j.1749-6632.2010.05823.x. View

Holick M, Binkley N, Bischoff-Ferrari H, Gordon C, Hanley D, Heaney R . Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(7):1911-30. DOI: 10.1210/jc.2011-0385. View

Ooi J, Chen J, Cantorna M . Vitamin D regulation of immune function in the gut: why do T cells have vitamin D receptors?. Mol Aspects Med. 2011; 33(1):77-82. PMC: 3781946. DOI: 10.1016/j.mam.2011.10.014. View

Ludidi S, Conchillo J, Keszthelyi D, van Avesaat M, Kruimel J, Jonkers D . Rectal hypersensitivity as hallmark for irritable bowel syndrome: defining the optimal cutoff. Neurogastroenterol Motil. 2012; 24(8):729-33, e345-6. DOI: 10.1111/j.1365-2982.2012.01926.x. View

Ford A, Talley N . Irritable bowel syndrome. BMJ. 2012; 345:e5836. DOI: 10.1136/bmj.e5836. View

Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E . Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther. 2012; 36(11-12):1009-31. DOI: 10.1111/apt.12080. View

Sprake E, Grant V, Corfe B . Vitamin D3 as a novel treatment for irritable bowel syndrome: single case leads to critical analysis of patient-centred data. BMJ Case Rep. 2012; 2012. PMC: 4544096. DOI: 10.1136/bcr-2012-007223. View

10.

Cantorna M, McDaniel K, Bora S, Chen J, James J . Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease. Exp Biol Med (Maywood). 2014; 239(11):1524-30. PMC: 4176535. DOI: 10.1177/1535370214523890. View

11.

von Kanel R, Muller-Hartmannsgruber V, Kokinogenis G, Egloff N . Vitamin D and central hypersensitivity in patients with chronic pain. Pain Med. 2014; 15(9):1609-18. DOI: 10.1111/pme.12454. View

12.

Andrae D, Covington P, Patrick D . Item-level assessment of the irritable bowel syndrome quality of life questionnaire in patients with diarrheal irritable bowel syndrome. Clin Ther. 2014; 36(5):663-79. DOI: 10.1016/j.clinthera.2014.04.009. View

13.

Tiwari S, Pratyush D, Gupta S, Singh S . Vitamin D deficiency is associated with inflammatory cytokine concentrations in patients with diabetic foot infection. Br J Nutr. 2014; 112(12):1938-43. DOI: 10.1017/S0007114514003018. View

14.

Chey W, Kurlander J, Eswaran S . Irritable bowel syndrome: a clinical review. JAMA. 2015; 313(9):949-58. DOI: 10.1001/jama.2015.0954. View

15.

Zhu T, Liu T, Shi Y, Zhao Q . Vitamin D/VDR signaling pathway ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis by inhibiting intestinal epithelial apoptosis. Int J Mol Med. 2015; 35(5):1213-8. PMC: 4380119. DOI: 10.3892/ijmm.2015.2150. View

16.

Flik C, van Rood Y, de Wit N . Systematic review: knowledge and educational needs of patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2015; 27(4):367-71. DOI: 10.1097/MEG.0000000000000252. View

17.

Khayyat Y, Attar S . Vitamin D Deficiency in Patients with Irritable Bowel Syndrome: Does it Exist?. Oman Med J. 2015; 30(2):115-8. PMC: 4412886. DOI: 10.5001/omj.2015.25. View

18.

Bashir M, Prietl B, Tauschmann M, Mautner S, Kump P, Treiber G . Effects of high doses of vitamin D3 on mucosa-associated gut microbiome vary between regions of the human gastrointestinal tract. Eur J Nutr. 2015; 55(4):1479-89. PMC: 4875045. DOI: 10.1007/s00394-015-0966-2. View

19.

Raftery T, Martineau A, Greiller C, Ghosh S, McNamara D, Bennett K . Effects of vitamin D supplementation on intestinal permeability, cathelicidin and disease markers in Crohn's disease: Results from a randomised double-blind placebo-controlled study. United European Gastroenterol J. 2015; 3(3):294-302. PMC: 4480538. DOI: 10.1177/2050640615572176. View

20.

Stokes C, Grunhage F, Baus C, Volmer D, Wagenpfeil S, Riemenschneider M . Vitamin D supplementation reduces depressive symptoms in patients with chronic liver disease. Clin Nutr. 2015; 35(4):950-7. DOI: 10.1016/j.clnu.2015.07.004. View